

## **Eurofins Eaton Analytical commits USD 1m of investments to reinforce UCMR3 capability**

**Monrovia, CA, 11 September 2012**

Eurofins Eaton Analytical announces that it has invested USD 1m in new equipment to support its UCMR3 analytical methods, strengthening its status as one of the most well-equipped drinking water laboratories in the country.

Following the latest Unregulated Contaminant Monitoring Rule (UCMR3), the US Environmental Protection Agency (EPA) requires all drinking water utilities serving more than 10,000 people to conduct extensive monitoring for 28 unregulated contaminants beginning as early as January 2013. This monitoring requires laboratories to perform analysis by up to seven analytical methods, including two liquid chromatography mass spectrometry (LC-MS-MS) methods for hormones and perfluorinated chemicals.

Given that several of the UCMR3 methods have very detailed requirements for sample collection of field blanks, with a requirement that any samples with positive detections have field blanks analyzed, it is crucial that laboratories intending to support utilities in this monitoring have extensive backup equipment for all of these methods, so that field blanks can be analyzed in a timely manner without requiring re-collection by utilities. The most recent investments of Eurofins Eaton Analytical were primarily for back-up instrumentation for all of the UCMR3 analytical methods. Once this new equipment is installed later this month, Eurofins Eaton Analytical will have dedicated backup equipment for every UCMR3 method, providing substantially more capacity than any other drinking water lab in the country. Eurofins Eaton Analytical was already the first commercial lab to be approved for all UCMR3 analytical methods ([UCMR3.EatonAnalytical.com](http://UCMR3.EatonAnalytical.com)), with approval being effective as of the date of Rule introduction.

New equipment includes several additional state-of-the-art LC-MS-MS systems, additional ion chromatographs, and GC-MS and GC-MS-MS systems. The laboratory will then have at least two, and in several cases three instruments that can be dedicated to each UCMR3 analysis. This ensures timely delivery of results and a high level of quality control.

Dr. Andy Eaton, Eurofins technical director, commented, *"We are committed to providing our clients with the highest quality and highest capacity UCMR3 services in the country to help ensure Rule compliance. This continues our UCMR1 and UCMR2 tradition of being the leader in UCMR analyses."*

**For more information, please visit [www.eatonanalytical.com](http://www.eatonanalytical.com) or contact:**

Ed Wilson  
President, Eurofins Eaton Analytical  
Phone: +1-626-386 1100  
E-mail: [edwilson@eurofinsus.com](mailto:edwilson@eurofinsus.com)

**Notes for the editor:**

**Eurofins – a global leader in bio-analysis**

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics and central laboratory services.

With over 12,000 staff in more than 170 laboratories across 32 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

**Important disclaimer:**

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.